Thomas Hielscher
Thomas Hielscher
DKFZ, German Cancer Research Center, Division of Biostatistics
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Driver mutations in histone H3. 3 and chromatin remodelling genes in paediatric glioblastoma
J Schwartzentruber, A Korshunov, XY Liu, DTW Jones, E Pfaff, K Jacob, ...
Nature 482 (7384), 226-231, 2012
Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma
D Sturm, H Witt, V Hovestadt, DA Khuong-Quang, DTW Jones, ...
Cancer cell 22 (4), 425-437, 2012
Medulloblastoma comprises four distinct molecular variants
PA Northcott, A Korshunov, H Witt, T Hielscher, CG Eberhart, S Mack, ...
Journal of clinical oncology 29 (11), 1408, 2011
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
F Sahm, D Schrimpf, D Stichel, DTW Jones, T Hielscher, S Schefzyk, ...
The lancet oncology 18 (5), 682-694, 2017
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma
H Witt, SC Mack, M Ryzhova, S Bender, M Sill, R Isserlin, A Benner, ...
Cancer cell 20 (2), 143-157, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
K Neben, HM Lokhorst, A Jauch, U Bertsch, T Hielscher, B van der Holt, ...
Blood, The Journal of the American Society of Hematology 119 (4), 940-948, 2012
Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma
J Hillengass, K Fechtner, MA Weber, T Bauerle, S Ayyaz, C Heiss, ...
J Clin Oncol 28 (9), 1606-1610, 2010
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation
G Leprivier, M Remke, B Rotblat, A Dubuc, ARF Mateo, M Kool, ...
Cell 153 (5), 1064-1079, 2013
Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
A Ward, A Balwierz, JD Zhang, M Küblbeck, Y Pawitan, T Hielscher, ...
Oncogene 32 (9), 1173-1182, 2013
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
EM Thompson, T Hielscher, E Bouffet, M Remke, B Luu, S Gururangan, ...
The lancet oncology 17 (4), 484-495, 2016
TERT promoter mutations and risk of recurrence in meningioma
F Sahm, D Schrimpf, A Olar, C Koelsche, D Reuss, J Bissel, A Kratz, ...
JNCI: Journal of the National Cancer Institute 108 (5), 2016
Adult medulloblastoma comprises three major molecular variants
M Remke, T Hielscher, PA Northcott, H Witt, M Ryzhova, A Wittmann, ...
Journal of clinical oncology 29 (19), 2717-2723, 2011
Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct
PA Northcott, T Hielscher, A Dubuc, S Mack, D Shih, M Remke, ...
Acta neuropathologica 122, 231-240, 2011
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del (17p), t (4; 14), gain 1q, hyperdiploidy, and tumor load
K Neben, A Jauch, T Hielscher, J Hillengass, N Lehners, A Seckinger, ...
Journal of clinical oncology 31 (34), 4325-4332, 2013
Cell competition is a tumour suppressor mechanism in the thymus
VC Martins, K Busch, D Juraeva, C Blum, C Ludwig, V Rasche, ...
Nature 509 (7501), 465-470, 2014
Molecular staging of intracranial ependymoma in children and adults
A Korshunov, H Witt, T Hielscher, A Benner, M Remke, M Ryzhova, ...
Journal of Clinical Oncology 28 (19), 3182-3190, 2010
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
D Hose, T Rème, T Hielscher, J Moreaux, T Messner, A Seckinger, ...
Haematologica 96 (1), 87, 2011
Combining information regarding chromosomal aberrations t (4; 14) and del (17p13) with the International Staging System classification allows stratification of myeloma patients …
K Neben, A Jauch, U Bertsch, C Heiss, T Hielscher, A Seckinger, T Mors, ...
Haematologica 95 (7), 1150, 2010
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
H Goldschmidt, HM Lokhorst, EK Mai, B van der Holt, IW Blau, ...
Leukemia 32 (2), 383-390, 2018
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma
M Remke, T Hielscher, A Korshunov, PA Northcott, S Bender, M Kool, ...
J Clin Oncol 29 (29), 3852-3861, 2011
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20